WO2003080114A3 - Imidazoquinoline adjuvants for vaccines - Google Patents

Imidazoquinoline adjuvants for vaccines Download PDF

Info

Publication number
WO2003080114A3
WO2003080114A3 PCT/GB2003/001203 GB0301203W WO03080114A3 WO 2003080114 A3 WO2003080114 A3 WO 2003080114A3 GB 0301203 W GB0301203 W GB 0301203W WO 03080114 A3 WO03080114 A3 WO 03080114A3
Authority
WO
WIPO (PCT)
Prior art keywords
vaccines
adjuvants
relates
nucleic acid
vaccine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2003/001203
Other languages
French (fr)
Other versions
WO2003080114A2 (en
Inventor
Ralph Patrick Braun
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Powderject Research Ltd
Original Assignee
Powderject Research Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/102,615 external-priority patent/US20030185835A1/en
Priority to JP2003577939A priority Critical patent/JP2005526793A/en
Priority to DE60335350T priority patent/DE60335350D1/en
Priority to CA002484049A priority patent/CA2484049A1/en
Priority to EP03712390A priority patent/EP1487485B1/en
Priority to SI200331940T priority patent/SI1487485T1/en
Application filed by Powderject Research Ltd filed Critical Powderject Research Ltd
Priority to DK03712390.8T priority patent/DK1487485T3/en
Priority to US10/508,143 priority patent/US20060088542A1/en
Priority to AU2003216851A priority patent/AU2003216851B2/en
Priority to AT03712390T priority patent/ATE491471T1/en
Publication of WO2003080114A2 publication Critical patent/WO2003080114A2/en
Publication of WO2003080114A3 publication Critical patent/WO2003080114A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The invention relates to the fields of vaccines, vaccine adjuvants, molecular biology and immunology, and generally relates to adjuvants and nucleic acid immunization techniques. More specifically, the invention relates to certain adjuvant compositions, and to vaccine and/or nucleic acid immunization strategies employing such compositions.
PCT/GB2003/001203 2002-03-19 2003-03-19 Imidazoquinoline adjuvants for vaccines Ceased WO2003080114A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
AT03712390T ATE491471T1 (en) 2002-03-19 2003-03-19 ADJUVANTS FOR DNA VACCINES BASED ON IMIDAZOCINOLINE
US10/508,143 US20060088542A1 (en) 2002-03-19 2003-03-19 Imidazoquinoline adjuvants for vaccines
CA002484049A CA2484049A1 (en) 2002-03-19 2003-03-19 Imidazoquinoline adjuvants for vaccines
EP03712390A EP1487485B1 (en) 2002-03-19 2003-03-19 Imidazoquinoline adjuvants for dna vaccines
SI200331940T SI1487485T1 (en) 2002-03-19 2003-03-19 Imidazoquinoline adjuvants for dna vaccines
JP2003577939A JP2005526793A (en) 2002-03-19 2003-03-19 Imidazoquinoline adjuvant for vaccine
DK03712390.8T DK1487485T3 (en) 2002-03-19 2003-03-19 Imidazoquinoline adjuvants for DNA vaccines
DE60335350T DE60335350D1 (en) 2002-03-19 2003-03-19 ADJUVANTIES FOR DNA VACCINES BASED ON IMIDAZOCHINOLINE
AU2003216851A AU2003216851B2 (en) 2002-03-19 2003-03-19 Imidazoquinoline adjuvants for vaccines

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US36605702P 2002-03-19 2002-03-19
US60/366,057 2002-03-19
US10/102,615 2002-03-19
US10/102,615 US20030185835A1 (en) 2002-03-19 2002-03-19 Adjuvant for vaccines

Publications (2)

Publication Number Publication Date
WO2003080114A2 WO2003080114A2 (en) 2003-10-02
WO2003080114A3 true WO2003080114A3 (en) 2003-11-06

Family

ID=28456582

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2003/001203 Ceased WO2003080114A2 (en) 2002-03-19 2003-03-19 Imidazoquinoline adjuvants for vaccines

Country Status (10)

Country Link
US (1) US20060088542A1 (en)
EP (1) EP1487485B1 (en)
JP (1) JP2005526793A (en)
AT (1) ATE491471T1 (en)
AU (1) AU2003216851B2 (en)
CA (1) CA2484049A1 (en)
DE (1) DE60335350D1 (en)
DK (1) DK1487485T3 (en)
PT (1) PT1487485E (en)
WO (1) WO2003080114A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7598382B2 (en) 2002-12-20 2009-10-06 Coley Pharmaceutical Group, Inc. Aryl substituted imidazoquinolines

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040265351A1 (en) 2003-04-10 2004-12-30 Miller Richard L. Methods and compositions for enhancing immune response
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
US7176214B2 (en) 2003-05-21 2007-02-13 Bristol-Myers Squibb Company Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
AU2004266162A1 (en) * 2003-08-25 2005-03-03 3M Innovative Properties Company Immunostimulatory combinations and treatments
NZ545412A (en) * 2003-08-27 2008-12-24 Coley Pharm Group Inc Aryloxy and arylalkyleneoxy substituted imidazoquinolines
KR101494056B1 (en) 2003-10-03 2015-02-16 쓰리엠 이노베이티브 프로퍼티즈 컴파니 Pyrazolopyridines and analogs thereof
EP1673087B1 (en) 2003-10-03 2015-05-13 3M Innovative Properties Company Alkoxy substituted imidazoquinolines
SG146662A1 (en) * 2003-10-10 2008-10-30 Powderject Vaccines Inc Method
AU2004293078B2 (en) 2003-11-25 2012-01-19 3M Innovative Properties Company Substituted imidazo ring systems and methods
WO2006009826A1 (en) * 2004-06-18 2006-01-26 3M Innovative Properties Company Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines
US8541438B2 (en) 2004-06-18 2013-09-24 3M Innovative Properties Company Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines
DE102004049223A1 (en) * 2004-10-08 2006-04-20 Johannes-Gutenberg-Universität Mainz Preparation for vaccination, vaccination and use of a vaccine preparation
CA2592904C (en) 2004-12-30 2015-04-07 3M Innovative Properties Company Chiral fused [1,2]imidazo[4,5-c] ring compounds
JP5313502B2 (en) 2004-12-30 2013-10-09 スリーエム イノベイティブ プロパティズ カンパニー Substituted chiral condensed [1,2] imidazo [4,5-c] cyclic compounds
JP2008530022A (en) 2005-02-04 2008-08-07 コーリー ファーマシューティカル グループ，インコーポレイテッド Aqueous gel formulation containing immune response modifier
US20080318998A1 (en) 2005-02-09 2008-12-25 Coley Pharmaceutical Group, Inc. Alkyloxy Substituted Thiazoloquinolines and Thiazolonaphthyridines
CA2602083A1 (en) 2005-02-09 2006-08-09 Coley Pharmaceutical Group, Inc. Oxime and hydroxylamine substituted thiazolo(4,5-c) ring compounds and methods
CA2597446A1 (en) * 2005-02-11 2006-08-31 Coley Pharmaceutical Group, Inc. Substituted imidazoquinolines and imidazonaphthyridines
AU2006216686A1 (en) * 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Method of preferentially inducing the biosynthesis of interferon
EP1851218A2 (en) * 2005-02-23 2007-11-07 3M Innovative Properties Company Hydroxyalkyl substituted imidazoquinoline compounds and methods
CA2598639A1 (en) 2005-02-23 2006-08-31 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazonaphthyridines
AU2006223634A1 (en) * 2005-02-23 2006-09-21 Coley Pharmaceutical Group, Inc. Hydroxyalkyl substituted imidazoquinolines
AU2006287270A1 (en) * 2005-09-09 2007-03-15 Coley Pharmaceutical Group, Inc. Amide and carbamate derivatives of N-{2-[4-amino-2- (ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-1,1-dimethylethyl}methanesulfonamide and methods
ZA200803029B (en) 2005-09-09 2009-02-25 Coley Pharm Group Inc Amide and carbamate derivatives of alkyl substituted /V-[4-(4-amino-1H-imidazo[4,5-c] quinolin-1-yl)butyl] methane-sulfonamides and methods
WO2007056112A2 (en) 2005-11-04 2007-05-18 Coley Pharmaceutical Group, Inc. Hydroxy and alkoxy substituted 1h-imidazoquinolines and methods
NZ567979A (en) * 2005-11-04 2012-02-24 Novartis Vaccines & Diagnostic Adjuvanted influenza vaccines including a cytokine-inducing agents which is an agonist of Toll-Like Receptor 7
EP1988896A4 (en) 2006-02-22 2011-07-27 3M Innovative Properties Co Immune response modifier conjugates
WO2007106854A2 (en) * 2006-03-15 2007-09-20 Coley Pharmaceutical Group, Inc. Hydroxy and alkoxy substituted 1h-imidazonaphthyridines and methods
BRPI0713711A2 (en) * 2006-06-20 2012-10-30 Transgene Sa recombinant viral vaccine, vaccination kit, and method for using at least one compound
WO2008010963A2 (en) * 2006-07-18 2008-01-24 3M Innovative Properties Company Immune response modifier formulations
US8178539B2 (en) * 2006-09-06 2012-05-15 3M Innovative Properties Company Substituted 3,4,6,7-tetrahydro-5H-1,2a,4a,8-tetraazacyclopenta[cd]phenalenes and methods
EP2244695A1 (en) * 2007-12-07 2010-11-03 Novartis AG Compositions for inducing immune responses
EP2286824B1 (en) * 2008-05-07 2013-08-14 Osaka University Non-covalent crosslinking agent for collagen
MX2011007559A (en) * 2009-01-20 2011-12-06 Myelin Repair Foundation Inc Compositions and methods for induction of antigen-specific tolerance.
LT2606047T (en) 2010-08-17 2017-04-10 3M Innovative Properties Company Lipidated immune response modifier compound compositions, formulations, and methods
JP5909745B2 (en) 2010-11-12 2016-04-27 クール ファーマシューティカルズ ディベロップメント カンパニー Drugs for inflammatory diseases as well as drugs for viral or bacterial infections
EP2717919B1 (en) 2011-06-03 2016-08-03 3M Innovative Properties Company Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom
CA2838023C (en) 2011-06-03 2019-08-13 3M Innovative Properties Company Hydrazino 1h-imidazoquinolin-4-amines and conjugates made therefrom
CA2876495C (en) 2012-06-21 2023-10-17 Northwestern University Peptide conjugated particles
HK1220368A1 (en) 2013-03-13 2017-05-05 Cour Pharmaceuticals Development Company Immune-modifying particles for the treatment of inflammation
CN105555301B (en) 2013-08-13 2021-04-16 西北大学 Peptide-conjugated particles
US9884866B2 (en) 2014-09-08 2018-02-06 Regents Of The University Of Minnesota Immunomodulators and immunomodulator conjugates
SG11201802769RA (en) 2015-10-29 2018-05-30 Novartis Ag Antibody conjugates comprising toll-like receptor agonist
US10730871B2 (en) 2016-01-28 2020-08-04 Regents Of The University Of Minnesota Immunomodulators and immunomodulator conjugates
EP3728255B1 (en) 2017-12-20 2022-01-26 3M Innovative Properties Company Amide substituted imidazo[4,5-c]quinoline compounds with a branched chain linking group for use as an immune response modifier
US12060350B2 (en) 2018-07-02 2024-08-13 Regents Of The University Of Minnesota Therapeutic compounds and methods of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993020847A1 (en) * 1992-04-16 1993-10-28 Minnesota Mining And Manufacturing Company Vaccine adjuvant
WO2002024225A1 (en) * 2000-09-20 2002-03-28 Glaxo Group Limited Use of immidazoquinolinamines as adjuvants in dna vaccination

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL73534A (en) * 1983-11-18 1990-12-23 Riker Laboratories Inc 1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US5238944A (en) * 1988-12-15 1993-08-24 Riker Laboratories, Inc. Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US4929624A (en) * 1989-03-23 1990-05-29 Minnesota Mining And Manufacturing Company Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
US5389640A (en) * 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5268376A (en) * 1991-09-04 1993-12-07 Minnesota Mining And Manufacturing Company 1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5266575A (en) * 1991-11-06 1993-11-30 Minnesota Mining And Manufacturing Company 2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
US5395937A (en) * 1993-01-29 1995-03-07 Minnesota Mining And Manufacturing Company Process for preparing quinoline amines
US5352784A (en) * 1993-07-15 1994-10-04 Minnesota Mining And Manufacturing Company Fused cycloalkylimidazopyridines
KR100341341B1 (en) * 1993-07-15 2002-11-25 미네소타 마이닝 앤드 매뉴팩춰링 캄파니 IMIDAZO[4,5-c]PYRIDIN-4-AMINES
US5482936A (en) * 1995-01-12 1996-01-09 Minnesota Mining And Manufacturing Company Imidazo[4,5-C]quinoline amines
US20010006950A1 (en) * 1998-02-11 2001-07-05 Juha Punnonen Genetic vaccine vector engineering
US6110929A (en) * 1998-07-28 2000-08-29 3M Innovative Properties Company Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
EP1005170B1 (en) * 1998-11-27 2002-02-13 STMicroelectronics S.r.l. Flash analog-to-digital converter
NZ512628A (en) * 1999-01-08 2004-03-26 3M Innovative Properties Co Formulations and methods for treatment of mucosal associated conditions with an immune response modifier
US6558951B1 (en) * 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
US6331539B1 (en) * 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
US20030190308A1 (en) * 2002-03-19 2003-10-09 Braun Ralph P. Adjuvant
JP2005533752A (en) * 2002-03-19 2005-11-10 パウダーメド リミテッド Imidazoquinolinamine as an adjuvant in HIV DNA vaccination
GB0206461D0 (en) * 2002-03-19 2002-05-01 Glaxo Group Ltd Improvements in vaccination

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993020847A1 (en) * 1992-04-16 1993-10-28 Minnesota Mining And Manufacturing Company Vaccine adjuvant
WO2002024225A1 (en) * 2000-09-20 2002-03-28 Glaxo Group Limited Use of immidazoquinolinamines as adjuvants in dna vaccination

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BURNS R P ET AL: "The imidazoquinolines, imiquimod and R-848, induced functional, but not phenotypic, maturation of human epidermal langerhans' cells", CLINICAL IMMUNOLOGY, ACADEMIC PRESS,, US, vol. 94, no. 1, January 2000 (2000-01-01), pages 13 - 23, XP002964628, ISSN: 1521-6616 *
DOCKRELL D H ET AL: "IMIQUIMOD AND RESIQUIMOD AS NOVEL IMMUNOMODULATORS", JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, SAUNDERS CO. LTD., LONDON, GB, vol. 48, no. 6, December 2001 (2001-12-01), pages 751 - 755, XP001037921, ISSN: 0305-7453 *
JOHNSON A G: "MOLECULAR ADJUVANTS AND IMMUNOMODULATORS: NEW APPROACHES TO IMMUNIZATION", CLINICAL MICROBIOLOGY REVIEWS, WASHINGTON, DC, US, vol. 7, no. 3, July 1994 (1994-07-01), pages 277 - 289, XP000942982, ISSN: 0893-8512 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7598382B2 (en) 2002-12-20 2009-10-06 Coley Pharmaceutical Group, Inc. Aryl substituted imidazoquinolines

Also Published As

Publication number Publication date
WO2003080114A2 (en) 2003-10-02
AU2003216851B2 (en) 2008-04-17
JP2005526793A (en) 2005-09-08
AU2003216851A1 (en) 2003-10-08
CA2484049A1 (en) 2003-10-02
DE60335350D1 (en) 2011-01-27
ATE491471T1 (en) 2011-01-15
PT1487485E (en) 2011-03-11
DK1487485T3 (en) 2011-03-14
US20060088542A1 (en) 2006-04-27
EP1487485B1 (en) 2010-12-15
EP1487485A2 (en) 2004-12-22

Similar Documents

Publication Publication Date Title
PT1487485E (en) Imidazoquinoline adjuvants for dna vaccines
WO2006068663A3 (en) Vaccine compositions for treating coronavirus infection
WO2004075829A3 (en) Adjuvanted influenza vaccine
WO2003049762A3 (en) Immunisation against chlamydia trachomatis
WO2003011223A3 (en) Immunomodulatory compounds and methods of use thereof
WO2005025614A3 (en) Improvements in vaccination
WO2007024941A3 (en) Polyvalent vaccine
DK1459766T3 (en) Adjuvant Compositions to Boost Immune Responses to Polynucleotide-Based Vaccines
WO2007095318A3 (en) Influenza antigens, vaccine compositions, and related methods
WO2004080403A3 (en) Influenza virus vaccine
IL214460A0 (en) Malaria prime/boost vaccines
WO2007075626A3 (en) Immunostimulatory activity of palindromic immune modulatory oligonucleotides (imo tm) contiaining different lengths of palindromic segments
WO2005013918A3 (en) Compositions, methods and kits relating to poxvirus subunit vaccines
WO2005007673A3 (en) Immunogenic peptides
WO2002087494A3 (en) Novel vaccine
WO2004045529A3 (en) West nile virus vaccine
WO2008048344A3 (en) Bacillus anthracis antigens, vaccine compositions, and related methods
WO2003051288A3 (en) Mycobacterial vaccine
EP2189473A3 (en) Nucleic and proteins from streptococcus groups A & B
WO2003041735A3 (en) Composotion comprising inhibitors of the notch signalling pathway for the modulation of the immune system
WO2009074861A3 (en) Improved vaccine
WO2002009752A3 (en) Immunological adjuvant compounds
WO2003080112A3 (en) Imidazoquinolineamines as adjuvants in hiv dna vaccination
WO2005048918A3 (en) Anthrax vaccine
AU2002327959A1 (en) Adjuvants for nucleic acid vaccines

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2484049

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2003577939

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2003216851

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003712390

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006088542

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10508143

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2003712390

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 10508143

Country of ref document: US